Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

By Rose McNulty

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

March 4th 2016

The Tightrope Act of Personalized Value in Cancer Care

Surabhi Dangi-Garimella, PhD

To discuss the challenges with the implementation of value tools, the Association of Community Cancer Centers invited a panel of experts during its 42nd annual meeting on policy, value, and quality in Washington, DC.

March 4th 2016

As "Me-Too" Options Expand, Cost, Side Effects Become Considerations, McCullough Explains

Choosing a therapy with fewer side effects can increase efficacy because patients stick with it, said Stacey McCullough, PharmD, of Tennessee Oncology.

March 4th 2016

Precision Therapeutics Can Pave the Path to Curing Cancer

Surabhi Dangi-Garimella, PhD

Immunotherapy represents the "next frontier" in cancer care, according to Joseph Alvarnas, MD, of City of Hope, who is editor-in-chief of Evidence-Based Oncology.

March 4th 2016

Becoming a More Educated e-Patient

After being diagnosed with a rare blood cancer, Jack Whelan has used his electronic connections to be more involved in his care.

March 3rd 2016

The Use of Expensive Scans in Lung and Esophageal Cancer Survivors

The is a wide variation across the country between hospitals using costly positron emission tomography scans for follow-up care for survivors of lung and esophageal cancers.

March 3rd 2016

How Can We Identify the Value of Personalized Medicine in Cancer?

Surabhi Dangi-Garimella, PhD

At Cancerscape, the Association of Community Cancer Center’s 42nd annual meeting on policy, value, and quality, Kavita Patel, MD, MS, spoke about the clinical imperatives of personalized medicine and the demonstration of value to all stakeholders.

March 3rd 2016

Kolodziej on Precision Medicine: Standardization, Transparency Needed in Data Collection

Broad treatment guidelines may be based on relatively narrow trial data.

March 3rd 2016

As Prospect of Risk for Doctors Looms, Cost Conversation Shifts in Cancer Care

Oncologists now face a cost discussion that was not part of their medical training. It's a balancing act between the big picture of understanding the burdens on the system and "the patient in front of you."

March 3rd 2016

ASCO President Reviews Post-SGR Challenges for Oncologists

Surabhi Dangi-Garimella, PhD

Keynote speaker Dr Julie Vose said the oncologist faces many administrative burdens in the transition to value-based care. Solving them is essential to spending more time with the patient.

March 2nd 2016

Hospital-Based Palliative Care Program Saves Costs and Improves QOL

Surabhi Dangi-Garimella, PhD

Two studies presented at the recently concluded 2016 Quality Care Symposium, hosted by the American Society of Clinical Oncology, proved that hospital-based palliative care programs achieve their proposed objectives.

March 2nd 2016

Diagnostic Testing Is a Wild West of Unknowns, Perils

The timely panel took place just after FDA issued a report on why it feels regulatory oversight of testing is necessary.

March 2nd 2016

Genetic Counselors Can Weed Out Errors, Ensure Patients Get Needed Tests, Larsen Haidle Says

A thorough family history is the foundation of precision medicine, according to the 2015 president of the National Society of Genetic Counselors.

March 2nd 2016

NICE Rejects Another Cancer Drug, Stresses Low Cost-Effectiveness

Surabhi Dangi-Garimella, PhD

Imbruvica, developed by Janssen for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who are unsuitable to receive chemo-immunotherapy, has been rejected by UK’s National Institute of Health and Care Excellence.

March 2nd 2016

Personalized Medicine Enters the "Postgenome Revolution"

Emanuel F. Petricoin III, PhD, said patients have much to gain from "democratization" as clinical trials move beyond academic centers.

March 1st 2016

Increased Cancer Risk Seen in Type 1 Diabetes, Study Finds

The authors said the incidence rates in type 1 diabetes compared with type 2 show that insulin treatment is not to blame for increased cancer rates.

March 1st 2016

Size Matters When It Comes to Cancer Drug Vials and Healthcare Waste, Says BMJ Study

Surabhi Dangi-Garimella, PhD

The pharmaceutical industry needs to rethink its approach to packaging cancer drugs into a one-size vial to avoid drug wastage and save over $1.7 billion in 2016.

March 1st 2016

What We're Reading: New HCV Drug Fails to Generate Excitement

What we're reading, March 1, 2016: physicians greet Merck's new hepatitis C drug with caution; 20% of Puerto Ricans could be infected with the Zika virus in 2016; and nearly $3 billion wasted in cancer medicines.

February 29th 2016

Healthcare Challenges and Solutions Discussed at the PAN-AJMC Cost-Sharing Roundtable

Surabhi Dangi-Garimella, PhD

The event saw participation by patient advocacy groups, health economists, health policy researchers, and patient advocacy groups-the primary interest of the participants was to identify the healthcare-associated economic hardships faced by patients and their caregivers across therapeutic areas and discuss potential solutions that could help alleviate some of this burden.

February 29th 2016

Chemotherapy Alone Post Surgery Provides Better Value in Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

Research led by investigators at the Vanderbilt University Medical Center has concluded that adjuvant chemotherapy improved survival compared with patients who received adjuvant chemoradiation in pancreatic cancer.

This Week in Managed Care: February 27, 2016

February 27th 2016

This Week in Managed Care: February 27, 2016

The top stories in managed care this week include findings on cancer survival disparities, CVS Health claimed drug spending growth slowed in 2015, and Horizon Blue Cross Blue Shield of New Jersey's OMNIA plan is interfering with existing patient-centered medical homes.

February 26th 2016

Making Healthcare Affordable Again - the Promise of Consumer Health Loans

Surabhi Dangi-Garimella, PhD

A new proposal from researchers at MIT and Dana-Farber offers a remedy for patients to cover high healthcare costs: securitized consumer healthcare loans.

February 25th 2016

Survival of the Fittest: Oncology Could Gain From Chemotherapy's Selective Force

Surabhi Dangi-Garimella, PhD

A new study questions the maximum-tolerated-dose approach in cancer.

Daniel J. Klein Highlights Barriers to Accessing Innovative Oncology Care

February 25th 2016

Daniel J. Klein Highlights Barriers to Accessing Innovative Oncology Care

There are multiple barriers to accessing innovative oncology care from the design of healthcare benefits to a patient’s position on the federal poverty level, explained Daniel J. Klein, president and CEO of the Patient Access Network (PAN) Foundation.

February 25th 2016

New Triage System Reduces ER Visits of Oncology Patients

Emergency room overutilization is a significant issue in oncology care and may increase healthcare expenditures while lowering the quality of patient care.

February 24th 2016

Brain Tumors Most Common Cause of Cancer Deaths in AYAs

Surabhi Dangi-Garimella, PhD

A collaborative study conducted across cancer treatment centers in the United States has identified malignant brain tumors as the most common cause of cancer-related deaths in adolescents and young adults aged 15 to 39 years.

February 24th 2016

What We're Reading: Drug Makers File Incomplete Side Effects Reports

What we're reading: drug makers are not reporting complete information about side effects; Johnson & Johnson will pay $72 million to the family of a woman who blamed her ovarian cancer on talcum powder; and Maine and Utah make new attempts at expanding Medicaid.

February 24th 2016

Investment in the National Cancer Moonshot - Hit or Miss?

Experts and biological researchers aren’t completely convinced with the president's cancer moonshot initiative and the released budget.

February 24th 2016

Income Inequality Contributes to Pediatric ALL Relapse

Surabhi Dangi-Garimella, PhD

Survival in children with acute lymphoblastic leukemia could be significantly influenced by their family’s socioeconomic status, a new study published in Pediatric Blood and Cancer has found.

February 23rd 2016

COA's Ted Okon to Discuss Oncology Trends in AJMC's February Tweetchat

Ted Okon, MBA, of the Community Oncology Alliance, will participate in a tweetchat with The American Journal of Managed Care on February 29, 1-2 pm ET, to discuss the 340B program, payment reform, the Oncology Medical Home, and more.

February 23rd 2016

BMJ Finds No Link Between Incretins and Pancreatic Cancer, but Debate Likely to Continue

BMJ's study found no link bewteen incretin-based drugs and pancreatic cancer but said because of the latency of the cancer, adverse effects would have to be watched.

...

107 108 109 110 111 112 113 114 115

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions